Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus BETIMOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus BETIMOL.
BETAPACE vs BETIMOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Nonselective beta-adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
1 drop of 0.25% or 0.5% solution in the affected eye(s) twice daily. If inadequate response, increase to 0.5% solution twice daily.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
2.5 to 5 hours (average 4 hours) in patients with normal renal function; may be prolonged in renal impairment (up to 8-10 hours).
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Primarily renal (unchanged drug and metabolites). Approximately 60-80% of a dose is excreted renally as unchanged timolol, with the remainder as inactive metabolites. Biliary/fecal excretion accounts for less than 20%.
Category C
Category C
Beta-Blocker
Beta-Blocker